Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.42 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 7/20 | 0.38 |
| ▸ | CNR1 | P21554 | 5/20 | 0.34 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | KIF11 | P52732 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21654074 | 0.98 | ESR1 (0.41) | ESR1ESR2MEN1KMT2ALMNA | |
| SCHEMBL22024340 | 0.83 | MEN1 (0.41) | ESR1ESR2MEN1KMT2ALMNA | |
| SCHEMBL22955761 | 0.82 | ESR1 (0.46) | ESR1ESR2MEN1KMT2ALMNA | |
| SCHEMBL21549391 | 0.82 | HDAC3 (0.45) | ESR1ESR2LMNACNR2CNR1 | |
| SCHEMBL21185893 | 0.81 | ESR1 (0.39) | ESR1ESR2LMNASMN1; SMN2CNR2 | |
| SCHEMBL19965676 | 0.81 | CNR2 (0.40) | ESR1ESR2CNR2CNR1 | |
| SCHEMBL21695082 | 0.80 | CNR2 (0.39) | ESR1ESR2LMNASMN1; SMN2CNR2 | |
| SCHEMBL19592942 | 0.80 | SMN1; SMN2 (0.41) | ESR1ESR2MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL20097921 | 0.79 | CNR2 (0.42) | ESR1ESR2CNR2CNR1 | |
| SCHEMBL18494777 | 0.79 | CNR2 (0.58) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11771677-B2 | Immunomodulating urea azalides | ZOETIS SERVICES LLC (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210015100-A1 | SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | SHENYANG SINOCHEM AGROCHEMICALS R&D CO., LTD. (CN) | 2021-01-21 | — | — | US | disclosed |
| US-10040766-B2 | Ubiquitination inhibitors | RIGEL PHARMACEUTICALS, INC. (US) | 2018-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210015100-A1 | SUBSTITUTED PYRIMIDINE COMPOUND AND PREPARATION METHOD AND USE THEREOF | GART, BROX, APRT | ESR1 4877/4885ESR2 4860/4885MEN1 1002/4885 |
| US-11771677-B2 | Immunomodulating urea azalides | ARG1, IL2, CD209 | ESR1 3811/4885ESR2 2535/4885MEN1 1099/4885 |
| US-10040766-B2 | Ubiquitination inhibitors | MDM2, RBX1, NEDD4 | ESR1 549/4885ESR2 922/4885MEN1 2624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.